prikaz prve stranice dokumenta Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice
  Preuzmi
PDF 612.16 KB
Znanstveni rad - Izvorni znanstveni rad
Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice
Pathology and Oncology Research, 27 (2021); 1609963. https://doi.org/10.3389/pore.2021.1609963
Čerina, Dora; Matković, Višnja; Katić, Kristina; Belac Lovasić, Ingrid; Šeparović, Robert; Canjko, Ivana; Jakšić, Blanka; Fröbe, Ana; Pleština, Stjepko; Bajić, Žarko; Vrdoljak, Eduard

Citirajte ovaj rad

Čerina, D., Matković, V., Katić, K., Belac Lovasić, I., Šeparović, R., Canjko, I. ... Vrdoljak, E. (2021). Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice. Pathology and Oncology Research, 27.. doi: 10.3389/pore.2021.1609963

Čerina, Dora, et al. "Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice." Pathology and Oncology Research, vol. 27, 2021. https://doi.org/10.3389/pore.2021.1609963

Čerina, Dora, Višnja Matković, Kristina Katić, Ingrid Belac Lovasić, Robert Šeparović, Ivana Canjko, Blanka Jakšić, et al. "Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice." Pathology and Oncology Research 27 (2021). https://doi.org/10.3389/pore.2021.1609963

Čerina, D., et al. (2021) 'Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice', Pathology and Oncology Research, 27. doi: 10.3389/pore.2021.1609963

Čerina D, Matković V, Katić K, Belac Lovasić I, Šeparović R, Canjko I, i sur.. Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice. Pathology and Oncology Research [Internet]. 27.09.2021. [pristupljeno 13.04.2024.];27. doi: 10.3389/pore.2021.1609963

D. Čerina, et al., "Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice", Pathology and Oncology Research, vol. 27, Rujan 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:777032. [Citirano: 13.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:777032
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice
AutorDora Čerina
AutorVišnja Matković
AutorKristina Katić
AutorIngrid Belac Lovasić
AutorRobert Šeparović
AutorIvana Canjko
AutorBlanka Jakšić
AutorAna Fröbe
AutorStjepko Pleština
AutorŽarko Bajić
AutorEduard Vrdoljak
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA PATOFIZIOLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Patofiziologija
Sažetak (engleski)
Comprehensive genomic profiling (CGP) is gradually becoming an inevitable part of the everyday oncology clinical practice. The interpretation and optimal implementation of the results is one of the hot topics of modern-day oncology. According to the recent findings, uterine cancer harbors a high level of gene alterations but is still insufficiently explored. The primary goal of this project was to assess the proportion of patients with targetable mutations. Also, the aim was to define and emphasize potential opportunities as well as the problems we have faced in the first year of testing on the national level. We performed a multicentric, retrospective, nested cross-sectional analysis on the total population of Croatian patients with advanced/metastatic uterine cancer where the tumor CGP was performed during 2020. CGP of the tumor tissue of 32 patients revealed clinically relevant genomic alterations (CRGA) in 27 patients (84%) with a median of 3 (IQR 1-4) CRGA per patient. The most common CRGAs were those of phosphatide-inositol-3 kinases (PIK3) in 22 patients (69%), with 13/22 (59%) of those patients harboring PIK3CA mutation. The next most common CGRAs were ARID1A and PTEN mutations in 13 (41%) and 11 (34%) patients, respectively. Microsatellite status was determined as stable in 21 patients (66%) and highly unstable in 10 patients (31%). A high tumor mutational burden (≥10Muts/Mb) was reported in 12 patients (38%). CGP analysis reported some kind of targeted therapy for 28 patients (88%). CGP determined clinically relevant genomic alterations in the significant majority of patients with metastatic uterine cancer, defining it as a rich ground for further positioning and development of precision oncology.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaPathology and Oncology Research
Brojčani podacivol. 27, 1609963
e-ISSN1532-2807
DOIhttps://doi.org/10.3389/pore.2021.1609963
URN:NBNurn:nbn:hr:105:777032
Datum objave publikacije2021-09-27
URL dokumentahttps://www.por-journal.com/articles/10.3389/pore.2021.1609963/full
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-04-07 08:04:43